×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for A
clinical
2,399 words
KG: Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for AD
2026-03-28
section:clinical-trials
kind:clinical-trial
topic:alzheimers
topic:immunotherapy
topic:interleukin-2
topic:regulatory-t-cells
Contents
Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for AD
Knowledge Graph
Related Hypotheses (18)
Ocular Immune Privilege Extension
Score: 0.47
TREM2-Dependent Microglial Senescence Transition
Score: 0.74
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.42
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.39
Synaptic Vesicle Tau Capture Inhibition
Score: 0.34
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 13 more
Related Analyses (11)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 6 more
Related Experiments (6)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Neural Stem Cell Therapy for Alzheimer's Disease
clinical · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.40
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.40
Show 1 more
Knowledge Graph (2 edges)
Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for AD
references
FOXP3
Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for AD
references
TREM2